Recently, Ding and co-authors showed that co-administration of IL-7 with tumour-reactive CD4+ Th cells promoted their expansion, persistence and anti-tumour activity in a mouse model, thus providing a rationale for using IL-7 as an adjuvant for CD4+ Th cell-based adoptive immunotherapy [198]. This evidence concerns the gene CD4 and neoplasm.